Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

Key facts

Sponsor

Hospital of Stomatology, Wuhan University

Principal Investigator

Gang Chen, M.D.

Hospital of Stomatology, Wuhan University

Intervention

Camrelizumab plus TP(drug)

Enrollment

309 enrolled

Eligibility

18-70 years · All sexes

Timeline

2023 – 2026

Study locations (3)

• Peking university Shenzhen hospital, Shenzhen, Guangdong, China
• Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
• Xiangya Hospital of Central South University, Changsha, Hunan, China

Collaborators

Jiangsu HengRui Medicine Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the oral tongue

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07402525
  Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
  Second Affiliated Hospital, School of Medicine, Zhejiang University
• RECRUITINGNCT07343271
  Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx
  University Hospital, Strasbourg, France
• RECRUITINGNCT06055868
  People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
  University of California, San Francisco
• RECRUITINGPHASE2, PHASE3NCT05893888
  Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma
  Privo Technologies
• RECRUITINGPHASE2NCT06485778
  A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma
  Memorial Sloan Kettering Cancer Center
• RECRUITINGNCT06321003
  SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
  University of Palermo
• ACTIVE NOT RECRUITINGPHASE2NCT06009861
  Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
  Peking University Hospital of Stomatology
• RECRUITINGPHASE2NCT05862168
  Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
  Weijia Fang, MD

See all trials for Squamous cell carcinoma of the oral tongue →